Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan, BCNU, vitamin B12b, and vitamin C with autologous stem cells in metastatic pancreatic and breast cancer
NCT04150042Phase 1Recruiting
- Sponsor
- General Oncology
- Start
- Jan 2021
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of melphalan in breast cancer, sponsored by General Oncology. Primary endpoints: Sinusoidal obstruction syndrome at 30 days, Idiopathic or Non-Infective Pulmonary Toxicity ≥ Grade 3 at 6 months and 9 more. Started Jan 2021; status: recruiting.
02
Drugs
melphalan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04150042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04150042.